From the perspective of practical application of clinical treatment of ovarian cancer, we evaluated the expression of common target genes of targeted drugs in ovarian cancer, we noticed the expression of PARP1, PARP2, platelet derived growth factor receptor alpha (PDGFRA), PDGFRB, and TGFB1 were significantly low expressed in low-risk group than that in high-risk group (Fig. 9c), which suggested that high-risk group patients may benefit from the corresponding targeted drugs. Here, TGFB1 is linked to ovarian cancer.